Cequent Seeks First Oral RNAi Trial

Xconomy Boston — 

Cequent Pharmaceuticals, the Cambridge, MA-based developer of RNA interference drug technology, said today it has filed an application with the FDA to begin the first clinical trial of an orally-delivered RNAi treatment. Cequent is seeking to test its drug, CEQ508, at a variety of doses in 18 patients with polyps that lead to colon cancer (familial adenomatous polyposis). Cequent hopes to get the trial underway before the end of March, at the Fred Hutchinson Cancer Research Center in Seattle.